Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Merger or Acquisition (May 2026)
10 slides from Gujarat Themis Biosyn's merger presentation, May 22, 2026
Slide 1: Gujarat Themis Biosyn Limited exchange filing cover letter
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/16 22nd May, 2026 Corporate Relationship Department Listing Department BSE
Slide 2: Gujarat Themis Biosyn Limited to Acquire MicroBiopharm Japan Co., Ltd.
Gujarat Themis Biosyn Limited to Acquire MicroBiopharm Japan Co., Ltd. Accelerating GTBL's Transition to Fermentation-based Globally Integrated CDMO
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited ("GTBL") solely for informational purposes in connection with the proposed acquisition of MicroBiopharm Japan Co., Ltd. ("MBJ"). This document is strictly confidential and is intended solely for the use of the individual
Slide 4: Table of Contents
Table of Contents 01 Transaction Details 02 About MicroBiopharm Japan 03 Strategic Rationale 04 Synergies & Value Creation Gujarat Themis Biosyn Limited
Slide 5: Transaction Details
01 | Transaction Details Structure Acquisition of 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ) via a wholly owned SPV incorporated in Japan Seller Funds managed or advised by T Capital Partners Co., Ltd. (Japan-based Private Equity Fund) JPY 21.5 Billion/Bn (~INR 1,300 Crore/Cr); funded throug
Slide 6: About MicroBiopharm
02 | About Microbiopharm Japan Co., Ltd. 60+ 3 Plants JPY 9.5 Bn Years of Experience GMP-Compliant, with FDA & PMDA (INR ~570 Cr) Approval Track Record FY 26E Revenue Business Mix KEY STRENGTHS Fermentation Developed Bacterial culture, microbial fermentation, large scale fermentation, Precision Phar
Slide 7: Strategic Rationale
03 | Strategic Rationale Accelerates GTBL's Transition Towards Fermentation-based Globally Integrated CDMO Precision Fermentation & Molecular Proprietary Products : APIs Advanced Biologics & Novel Modalities Engineering Entry into precision fermentation through MBJ's Supply of API/Intermediates for
Slide 8: Synergies & Value Creation
04 | Synergies & Value Creation Enhanced Fermentation & Precision Biotech Capabilities 1 Strengthens fermentation capabilities and enables entry into precision fermentation via proprietary P450 enzyme libraries — reducing reliance on traditional chemical routes Expanded Product Portfolio & Therapeut
Slide 9: Contact Information
Contact Information Gujarat Themis Biosyn Limited Investor Relations — Adfactors PR Mr. Krupesh Patel Mr. Rahul Trivedi / Ms. Saloni Nagvekar Chief Financial Officer Investor Relations Email: krupesh.patel@themismedicare.com rahul.trivedi@adfactorspr.com Email: saloni.nagvekar@adfactorspr.com Web: w
Slide 10: Thank You
Thank You Building Fermentation-based Globally Integrated CDMO Gujarat Themis Biosyn Limited | www.gtbl.in
Gujarat Themis Biosyn — Merger or Acquisition (May 2026) on 6ix